An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease

Last updated: February 21, 2024
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Overall Status: Active - Recruiting

Phase

1

Condition

Gaucher Disease

Treatment

VGN-R08b

Clinical Study ID

NCT06272149
VGN-R08b-001
  • Ages < 24
  • All Genders

Study Summary

This exploratory trial is to prove the tolerability and safety of VGN-R08b to treat infants with type II Gaucher disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Infants with age of ≤24 months.
  2. Historical diagnosis of Gaucher disease confirmed by GCase enzyme activity test, andwith GBA1 biallelic mutations.
  3. Neurological signs and/or symptoms consistent with diagnosis of GD2.
  4. Parent(s)/legal guardian(s) of subject must give their consent for subject to enrollin the study.
  5. Parent(s)/legal guardian(s) of the subject must agree to comply with the requirementsof the study, including providing disease information and support disease assessmentof symptoms.

Exclusion

Exclusion Criteria:

  1. Diagnosis of a significant CNS disease other than GD2 that may be a cause for thepatient's GD symptoms or may confound study objectives.
  2. Achieved independent gait.
  3. Severe visceral symptoms of GD which, in the opinion of the Investigator, would posean unacceptable risk to the patient or interfere with the patient's ability to complywith study procedures or interfere with the conduct of the study.
  4. Clinically active infection (including HIV, HBV, HCV or syphilis).
  5. For those receiving enzyme replacement therapy and/or substrate reduction therapyand/or ambroxol for Gaucher disease, stable treatment ≤2 months before enrollment.
  6. Use of strong inhibitors or inducers of cytochrome CYP3A4 or P-glycoprotein (P-gp)medications, herbals, or over-the-counter agents.
  7. Any type of prior gene or cell therapy.
  8. Immunizations (live vaccines) in the prior 4 weeks.
  9. Use of systemic immunosuppressant or corticosteroid therapy other thanprotocol-specified (topical preparations for dermatological conditions are allowed).
  10. Patients with anti-AAV9 neutralizing antibody titer over 1:5.
  11. Brain MRI (magnetic resonance imaging) showing clinically significant abnormalityconsidered to prevent intracisternal injection.
  12. Contraindication to sedation during surgery or imaging studies (PET).
  13. Presence of other significant medical conditions that would create an unacceptablerisk to the patient or interfere with the patient's ability to comply with studyprocedures or interfere with the conduct of the study.

Study Design

Total Participants: 6
Treatment Group(s): 1
Primary Treatment: VGN-R08b
Phase: 1
Study Start date:
March 01, 2023
Estimated Completion Date:
February 28, 2029

Study Description

Gaucher disease (GD) is an autosomal recessive genetic metabolic disorder. Due to the mutation of Glucocerebrosidase gene (GBA1), the activity of glucocerebrosidase (GCase) in the lysosome of the body is reduced, causing its substrate glucocerceramide to be accumulated in macrophage lysosomes in the liver, spleen, bone, lung, brain and eyes. Type II, acute neuropathy, with extensive and severe visceral involvement, usually develops within the first year of life, and most children die before the age of 2. VGN-R08b is a kind of Gene therapy with adeno-associated virus (AAV) serotype 9 (AAV9) driven human GBA1 being injected directly into intracerebroventricular.

This is a single-center, open, dose-climbing investigator-sponsored exploratory clinical study that included a dose-climbing phase and a dose-expanding phase. The sponsor plans to explore two dose levels in dose-climbing phase (one subject each cohort), then have additional 2~4 subjects in dose-expanding phase.

This study is to give preliminary evidence for the safety and efficacy of VGN-R08b treatment for patients with type II Gaucher disease.

Connect with a study center

  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai 200097
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.